Baxano Surgical pullback brings attractive risk/reward, says Brean Capital Brean Capital believes the recent pullback in shares of Baxano Surgical provides a compelling risk/reward profile relative to its $4 price target. Brean thinks that if Baxano can prove itself over the next two years, it is likely to be taken out. The firm reiterates a Buy rating on the name.
News For BAXS From The Last 14 Days
Check below for free stories on BAXS the last two weeks.